IL256052A - Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer - Google Patents

Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer

Info

Publication number
IL256052A
IL256052A IL256052A IL25605217A IL256052A IL 256052 A IL256052 A IL 256052A IL 256052 A IL256052 A IL 256052A IL 25605217 A IL25605217 A IL 25605217A IL 256052 A IL256052 A IL 256052A
Authority
IL
Israel
Prior art keywords
cancer
compositions
immunotherapeutic agent
treating cancer
stemness inhibitor
Prior art date
Application number
IL256052A
Other languages
English (en)
Hebrew (he)
Original Assignee
Boston Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Biomedical Inc filed Critical Boston Biomedical Inc
Publication of IL256052A publication Critical patent/IL256052A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Furan Compounds (AREA)
IL256052A 2015-06-03 2017-12-03 Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer IL256052A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562170498P 2015-06-03 2015-06-03
US201562233081P 2015-09-25 2015-09-25
PCT/US2016/035721 WO2016196935A1 (en) 2015-06-03 2016-06-03 Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer

Publications (1)

Publication Number Publication Date
IL256052A true IL256052A (en) 2018-01-31

Family

ID=56133104

Family Applications (1)

Application Number Title Priority Date Filing Date
IL256052A IL256052A (en) 2015-06-03 2017-12-03 Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer

Country Status (15)

Country Link
US (1) US20180140572A1 (https=)
EP (1) EP3302462A1 (https=)
JP (2) JP2018521979A (https=)
KR (1) KR20180015195A (https=)
CN (1) CN107847481A (https=)
AU (1) AU2016271475A1 (https=)
BR (1) BR112017026025A2 (https=)
CA (1) CA2988126A1 (https=)
EA (1) EA201792623A1 (https=)
HK (1) HK1245632A1 (https=)
IL (1) IL256052A (https=)
MX (1) MX2017015618A (https=)
PH (1) PH12017502195A1 (https=)
TW (1) TW201717935A (https=)
WO (1) WO2016196935A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3050566B1 (en) 2007-09-10 2018-11-28 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
EP2983790A2 (en) 2013-04-09 2016-02-17 Boston Biomedical, Inc. Methods for treating cancer
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
WO2017132049A1 (en) * 2016-01-20 2017-08-03 Boston Biomedical, Inc. Methods for treating cancer
CN109790220A (zh) 2016-08-25 2019-05-21 豪夫迈·罗氏有限公司 与巨噬细胞激活剂组合的抗csf-1r抗体的间歇给药
JP7106563B2 (ja) 2016-11-29 2022-07-26 スミトモ ファーマ オンコロジー， インコーポレイテッド ナフトフラン誘導体、その調製、および使用方法
KR20190103156A (ko) * 2016-12-20 2019-09-04 에테하 취리히 암에서 비-유전적 약물 내성 프로그램을 표적으로 하는 약물의 동정
CN110072553B (zh) 2016-12-22 2023-09-15 豪夫迈·罗氏有限公司 在抗pd-l1/pd1治疗失败之后抗csf-1r抗体与抗pd-l1抗体组合对肿瘤的治疗
WO2018160887A1 (en) * 2017-03-01 2018-09-07 Boston Biomedical, Inc. Pdl1-specific and beta-catenin-specific asymmetric interfering rna compositions, uses or preparation thereof
CA3062656A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer
WO2018232230A1 (en) * 2017-06-15 2018-12-20 Cancer Advances Inc. Compositions and methods for inducing humoral and cellular immunities against tumors and cancer
US12150978B2 (en) 2017-06-15 2024-11-26 Cancer Advances Inc. Compositions and methods for preventing tumors and cancer
EP3870161A1 (en) * 2018-10-23 2021-09-01 Université catholique de Louvain Guanabenz as an adjuvant for immunotherapy
CN109675040B (zh) * 2018-12-31 2021-07-30 清华大学 治疗乳腺癌的组合物及其应用
EP3714883A1 (en) * 2019-03-25 2020-09-30 AC BioScience SA Indole containing small chemical compounds and use thereof for the non-cytotoxic and immunological treatment of cancer
CN113891709A (zh) * 2019-04-02 2022-01-04 德克萨斯大学系统董事会 用于治疗疾病的转录抑制剂和免疫检验点抑制剂的组合
JPWO2021039616A1 (https=) * 2019-08-23 2021-03-04
EP4118238A4 (en) * 2020-03-12 2024-04-17 Personal Genome Diagnostics Inc. MICROSATELLITE INSTABILITY SIGNATURES
CN112530581B (zh) * 2020-12-03 2023-11-21 安徽医科大学第一附属医院 一种前列腺癌患者的免疫分子分类系统及其应用

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846534A (en) 1988-02-12 1998-12-08 British Technology Group Limited Antibodies to the antigen campath-1
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
MD1367C2 (ro) 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
GB9603507D0 (en) 1996-02-20 1996-04-17 Isis Innovation Antibody variants
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US20020173629A1 (en) 1997-05-05 2002-11-21 Aya Jakobovits Human monoclonal antibodies to epidermal growth factor receptor
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
JP2003525862A (ja) * 1999-01-27 2003-09-02 ザ ユニヴァーシティー オブ サウス フロリダ ヒト癌の治療のためのｓｔａｔ３シグナル伝達の阻害
EP1897540A3 (en) * 1999-01-27 2008-07-23 University Of South Florida Inhibition of STAT3 signal transduction for human cancer therapy
IL148079A0 (en) 1999-08-24 2002-09-12 Medarex Inc Human ctla-4 antibodies and compositions containing the same
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
ATE513563T1 (de) 2000-10-09 2011-07-15 Isis Innovation Therapeutische und toleranz-induzierende antikörper
US7090843B1 (en) 2000-11-28 2006-08-15 Seattle Genetics, Inc. Recombinant anti-CD30 antibodies and uses thereof
US7435797B2 (en) 2002-04-10 2008-10-14 Genentech, Inc. Anti-HER2 antibody variants
ES2350687T3 (es) 2002-07-03 2011-01-26 Ono Pharmaceutical Co., Ltd. Composiciones de inmunopotenciación.
EP2357009A1 (en) 2002-07-15 2011-08-17 Board of Regents, The University of Texas System Duramycin peptide binding to anionic phospholipids and aminophospholipids conjugates and their use in treating viral infections
CN101928344B (zh) 2002-10-17 2014-08-13 根马布股份公司 抗cd20的人单克隆抗体
CN102558352A (zh) 2003-06-27 2012-07-11 艾默根佛蒙特有限公司 针对表皮生长因子受体的缺失突变体的抗体及其使用
US7758859B2 (en) 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
WO2005042581A2 (en) 2003-11-01 2005-05-12 Biovation Ltd. Modified anti-cd52 antibody
EP2287195B1 (en) 2004-07-01 2019-05-15 Novo Nordisk A/S Pan-kir2dl nk-receptor antibodies and their use in diagnostik and therapy
KR20140032004A (ko) 2004-07-22 2014-03-13 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
US7951374B2 (en) * 2004-12-14 2011-05-31 University Of South Florida Methods for inhibiting STAT3 signaling in immune cells
RU2494107C2 (ru) 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
US20070009532A1 (en) 2005-07-06 2007-01-11 Branimir Sikic Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar
HRP20131167T1 (hr) 2007-06-18 2014-01-03 Merck Sharp & Dohme B.V. Antitijela za humani receptor programirane smrti pd-1
JP2010537640A (ja) 2007-08-27 2010-12-09 ボストン バイオメディカル， インコーポレイテッド マイクロｒｎａ模倣剤または阻害剤としての非対称性ｒｎａ二重鎖の組成物
EP3050566B1 (en) * 2007-09-10 2018-11-28 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
WO2010014784A2 (en) 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
EP2998405B1 (en) 2009-05-13 2019-12-11 Genzyme Corporation Anti-human cd52 immunoglobulins
NZ628923A (en) 2009-11-24 2016-02-26 Medimmune Ltd Targeted binding agents against b7-h1
WO2011084694A1 (en) * 2009-12-17 2011-07-14 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Stabilized stat3 decoy oligonucleotides and uses therefor
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
JP5998060B2 (ja) 2010-03-04 2016-09-28 マクロジェニクス，インコーポレーテッド Ｂ７−ｈ３と反応性のある抗体、その免疫学的に活性なフラグメントおよびその使用
RU2571661C2 (ru) 2010-03-19 2015-12-20 Бостон Байомедикал, Инк. Новые соединения и композиции для нацеливания на злокачественные стволовые клетки
PT2547205T (pt) * 2010-03-19 2024-05-27 1Globe Biomedical Co Ltd Novos métodos para atingir células estaminais cancerígenas
EP2547205B1 (en) 2010-03-19 2024-03-20 1Globe Biomedical Co., Ltd. Novel methods for targeting cancer stem cells
US9150530B2 (en) 2011-03-04 2015-10-06 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. Esters of 4, 9-dihydroxy-naphtho [2, 3-b] furans for disease therapies
ES2676205T3 (es) 2011-03-31 2018-07-17 Merck Sharp & Dohme Corp. Formulaciones estables de anticuerpos para el receptor PD-1 humano de muerte programada y tratamientos relacionados
US8977803B2 (en) 2011-11-21 2015-03-10 Western Digital Technologies, Inc. Disk drive data caching using a multi-tiered memory
CN113967253A (zh) * 2012-05-15 2022-01-25 百时美施贵宝公司 通过破坏pd-1/pd-l1信号传输的免疫治疗
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
EP2983790A2 (en) 2013-04-09 2016-02-17 Boston Biomedical, Inc. Methods for treating cancer
US10005752B2 (en) * 2014-06-09 2018-06-26 Kyoto Pharmaceutical Industries, Ltd. Anticancer agent
WO2016030455A1 (en) 2014-08-28 2016-03-03 Medimmune Limited Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small lung cancer

Also Published As

Publication number Publication date
US20180140572A1 (en) 2018-05-24
BR112017026025A2 (pt) 2018-08-14
KR20180015195A (ko) 2018-02-12
WO2016196935A1 (en) 2016-12-08
HK1245632A1 (zh) 2018-08-31
JP2020169223A (ja) 2020-10-15
TW201717935A (zh) 2017-06-01
PH12017502195A1 (en) 2018-06-04
JP2018521979A (ja) 2018-08-09
CN107847481A (zh) 2018-03-27
CA2988126A1 (en) 2016-12-08
MX2017015618A (es) 2018-08-15
AU2016271475A1 (en) 2017-12-21
EA201792623A1 (ru) 2018-04-30
EP3302462A1 (en) 2018-04-11

Similar Documents

Publication Publication Date Title
IL256052A (en) Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer
IL304820A (en) Preparations and methods for the treatment of cancer
IL272877A (en) SHP2 inhibitory compositions and methods for cancer treatment
IL267247B (en) Compositions and methods for treating cancer
IL266053A (en) Preparations and methods for the treatment of ezh2-mediated cancer
ZA201904695B (en) Amino-triazolopyridine compounds and their use in treating cancer
IL256523A (en) Compositions and methods for treating cancer
SMT202100273T1 (it) Metodi e composizioni per il trattamento del cancro
LT3189074T (lt) Kompozicijos ir būdai skirti uždegimo gydymui ir prevencijai
IL325803A (en) Materials and methods for cancer treatment
IL255638A (en) Compositions and methods for treating cancer
SMT202100207T1 (it) Inibitori della farnesiltransferasi per il trattamento del cancro
GB201702160D0 (en) Inhibitors for use in therapy
SG10202013112YA (en) Zinc-gamma-pga compositions and methods for treating cancer
SG11202002123XA (en) Compositions and methods for treating liver cancer
IL271923A (en) Methods and compositions for treating addictions
SMT202200151T1 (it) Composizioni e metodi per l’uso nel trattamento di omocistinuria.
IL261648A (en) Cinnolin-4-amine compounds and their use in treating cancer
IL259358A (en) Bis-pyridazine compounds and their use in treating cancer
IL272782A (en) Preparations and methods for the treatment of cancer
IL272945A (en) Local preparations and methods of treatment
ZA201802268B (en) Methods and compositions for preventing or treating cancer
SG10201912086QA (en) Compositions and methods for treating cancer
ZA201904626B (en) Cancer treatment method and composition
GB2560769B (en) Compounds and compositions for use in treating psoriasis